Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024
Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024
Karyopharm周六在ASCO 2024上介绍了SIENDO关于晚期或复发性TP53野生型子宫内膜癌研究的最新探索性亚组分析
Karyopharm On Saturday, Presented Updated Exploratory Subgroup Analyses From SIENDO Study on Advanced or Recurrent TP53 Wild-Type Endometrial Cancer at ASCO 2024
Karyopharm周六在ASCO 2024上介绍了SIENDO关于晚期或复发性TP53野生型子宫内膜癌研究的最新探索性亚组分析